Targeting genetic diseases

Israel’s Averna Therapeutics (formerly Exsilio Therapeutics) is using gene editing to develop medicines to cure rare genetic diseases. Averna’s leadership includes Tal Zaks who was Chief Medical Officer at Covid-19 vaccine developer Moderna. Averna has already raised $82 million in funds.

https://en.globes.co.il/en/article-tal-zaks-israeli-startup-targets-rare-genetic-diseases-1001500636

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *